Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CSBR 
Champions Oncology Inc (CSBR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/21/2025: CSBR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 41.28% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 122.37M USD | Price to earnings Ratio 19.67 | 1Y Target Price 12 |
Price to earnings Ratio 19.67 | 1Y Target Price 12 | ||
Volume (30-day avg) 81145 | Beta 0.2 | 52 Weeks Range 3.60 - 11.99 | Updated Date 04/2/2025 |
52 Weeks Range 3.60 - 11.99 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-10 | When After Market | Estimate -0.01 | Actual 0.33 |
Profitability
Profit Margin 10.97% | Operating Margin (TTM) 26.4% |
Management Effectiveness
Return on Assets (TTM) 14.64% | Return on Equity (TTM) 37.68% |
Valuation
Trailing PE 19.67 | Forward PE 22.88 | Enterprise Value 122284643 | Price to Sales(TTM) 2.09 |
Enterprise Value 122284643 | Price to Sales(TTM) 2.09 | ||
Enterprise Value to Revenue 2.09 | Enterprise Value to EBITDA 14.51 | Shares Outstanding 13826900 | Shares Floating 5109536 |
Shares Outstanding 13826900 | Shares Floating 5109536 | ||
Percent Insiders 25.88 | Percent Institutions 47.79 |
Analyst Ratings
Rating 5 | Target Price 8 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Champions Oncology Inc
Company Overview
History and Background
Champions Oncology Inc. was founded in 2007. It specializes in providing advanced preclinical oncology solutions to biopharmaceutical companies to help accelerate and improve drug development.
Core Business Areas
- TumorGraft Platform: Champions' TumorGraft platform involves implanting a patient's tumor into an immunodeficient mouse to create a Patient-Derived Xenograft (PDX) model. These models are then used to test the efficacy of various cancer therapies.
- BioPharma Services: Champions offers a range of services, including preclinical drug testing, biomarker discovery, and translational research. These services are designed to help biopharmaceutical companies develop and refine their cancer therapies.
- Data Analytics: The company provides data analytics and bioinformatics services to help clients interpret the results of their preclinical studies.
Leadership and Structure
Champions Oncology Inc. is led by a management team with expertise in oncology, drug development, and business management. The organizational structure is designed to support the company's core business areas.
Top Products and Market Share
Key Offerings
- TumorGraft Studies: Patient-Derived Xenograft (PDX) studies for preclinical drug development. Market share data is difficult to pinpoint precisely but Champions is a significant player in the PDX market. Competitors include Charles River Laboratories, Crown Bioscience (JSR Corporation), and The Jackson Laboratory. Revenue generated from this is not broken out in detail.
- Biomarker Analysis: Services to identify and validate biomarkers for cancer drug development. Market share is varied and not readily available. Competition includes companies that provide Next Generation Sequencing services such as Illumina and Thermo Fisher Scientific. Revenue generated from this is not broken out in detail.
Market Dynamics
Industry Overview
The industry focuses on preclinical oncology research services, which is experiencing growth due to increased investment in cancer drug development and the need for more predictive preclinical models.
Positioning
Champions Oncology Inc. is positioned as a provider of advanced preclinical oncology solutions with its TumorGraft platform. Its competitive advantage lies in its ability to create and utilize PDX models that closely mimic patient tumors.
Total Addressable Market (TAM)
The TAM for preclinical oncology research services is estimated to be in the billions of dollars. Champions is positioned to capture a portion of this market through its PDX models and other services.
Upturn SWOT Analysis
Strengths
- Proprietary TumorGraft platform
- Experienced management team
- Strong customer relationships
- Data analytics capabilities
Weaknesses
- Reliance on preclinical research spending
- Competition from larger CROs
- Limited geographic presence
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships with biopharmaceutical companies
- Development of new preclinical models
- Growing demand for personalized medicine solutions
Threats
- Changes in regulatory requirements
- Economic downturn affecting research spending
- Emergence of new preclinical technologies
- Competition from other service providers
Competitors and Market Share
Key Competitors
- Charles River Laboratories (CRL)
- Crown Bioscience (private)
- The Jackson Laboratory (private)
Competitive Landscape
Champions Oncology Inc. is competing in a market with established players. Its competitive advantage is based on its specialized PDX models.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Champions Oncology Inc. has experienced growth in revenue due to increased demand for its preclinical services.
Future Projections: Future growth is expected to be driven by continued investment in cancer drug development and the company's expansion into new markets.
Recent Initiatives: Recent initiatives include strategic partnerships, investment in new technologies, and expansion of service offerings.
Summary
Champions Oncology Inc. is a specialized preclinical oncology services provider with a unique TumorGraft platform. The company has experienced growth and is well-positioned to capitalize on future opportunities in the cancer drug development market. Key strengths include proprietary technology and strong customer relationships, but competition and reliance on research spending pose challenges.
Similar Companies
CRL
Charles River Laboratories
CRL
Charles River Laboratories
ILMN
Illumina Inc
ILMN
Illumina Inc
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Champions Oncology Inc. website
- Company SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Champions Oncology Inc
Exchange NASDAQ | Headquaters Hackensack, NJ, United States | ||
IPO Launch date 2003-01-10 | CEO & Director Dr. Ronnie Morris M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 210 | |
Full time employees 210 | |||
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.